Released Mar 16, 2017, before the open
10-K filed Mar 16, 2017, 75 days after period end · 0001193125-17-084396
Q4 2016 · 10-K
Revenue$47.00K$47.00K +88.0% vs Q4 2015−2.1% vs Q3 2016
Net Income-$26.94M-$26.94M N/M vs Q4 2015N/M vs Q3 2016
EPS Diluted-$0.65-$0.65 N/M vs Q4 2015N/M vs Q3 2016
Operating Income-$27,165,000N/M
Operating Cash Flowderived-$19,998,000N/M
Free Cash Flowderived-$20,023,000N/M
Margins · derived
Operating margin-57797.9%+59414.1 pt vs Q4 2015
Net margin-57308.5%+58875.5 pt vs Q4 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2016 | Q4 2015 | Q4 2014 | Q4 2013 |
|---|---|---|---|---|
| Revenue | $47.00K | $25.00K | $16.00K | $21.00K |
| Net Income | -$26.94M | -$29.05M | -$25.93M | — |
| EPS Diluted | -$0.65 | -$0.81 | -$0.79 | -$0.72 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR